Omata M.Kanda T.Wei L.Yu M.-L.Chuang W.-L.Ibrahim A.Lesmana C.R.A.Sollano J.Kumar M.Jindal A.Sharma B.C.Hamid S.S.Dokmeci A.K.Mamun-Al-Mahtab, McCaughan G.W.McCaughan G.W.Mamun-Al-MahtabWasim J.Crawford D.H.G.JIA-HORNG KAOYokosuka O.Lau G.K.K.Sarin S.K.2021-09-042021-09-0420161936-0533https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964691124&doi=10.1007%2fs12072-016-9717-6&partnerID=40&md5=2688291a183ff5effab7076beec29ad8https://scholars.lib.ntu.edu.tw/handle/123456789/581904The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the “APASL consensus statements and recommendation on management of hepatitis C” in March, 2015, in order to revise “APASL consensus statements and management algorithms for hepatitis C virus infection (Hepatol Int 6:409–435, 2012)”. The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations on treatment of hepatitis C are presented in this review. ? 2016, The Author(s).APASL; DAAs; HCV; Interferon-free; Turkey[SDGs]SDG3asunaprevir; beclabuvir; daclatasvir; dasabuvir; elbasvir; grazoprevir; ledipasvir plus sofosbuvir; ombitasvir; paritaprevir; peginterferon; proteinase inhibitor; ribavirin; ritonavir; antivirus agent; adult; antiviral therapy; cancer recurrence; chronic kidney disease; decompensated liver cirrhosis; drug approval; Egypt; female; gene; graft recipient; health care organization; hepatitis B; hepatitis C; Hepatitis C virus genotype 1; Hepatitis C virus genotype 2; Hepatitis C virus genotype 3; Hepatitis C virus genotype 4; Hepatitis C virus genotype 5; Hepatitis C virus genotype 6; human; Human immunodeficiency virus infection; IL28B gene; Indonesia; infection control; kidney failure; licence; liver cell carcinoma; liver transplantation; major clinical study; male; mixed infection; multicenter study (topic); Pakistan; phase 2 clinical trial (topic); phase 3 clinical trial (topic); portal hypertension; practice guideline; priority journal; randomized controlled trial (topic); Review; single nucleotide polymorphism; clinical trial (topic); consensus development; disease management; drug effects; genetics; Hepacivirus; Hepatitis C, Chronic; treatment outcome; virology; virus load; Antiviral Agents; Clinical Trials as Topic; Disease Management; Hepacivirus; Hepatitis C, Chronic; Humans; Practice Guidelines as Topic; Treatment Outcome; Viral LoadReview10.1007/s12072-016-9717-6271304272-s2.0-84964691124